HK1158647A1 - 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazo as 5-hydroxytryptamine-6 ligands 5--6 1-()-4-(-1-)-1h- - Google Patents

1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazo as 5-hydroxytryptamine-6 ligands 5--6 1-()-4-(-1-)-1h-

Info

Publication number
HK1158647A1
HK1158647A1 HK11113150.6A HK11113150A HK1158647A1 HK 1158647 A1 HK1158647 A1 HK 1158647A1 HK 11113150 A HK11113150 A HK 11113150A HK 1158647 A1 HK1158647 A1 HK 1158647A1
Authority
HK
Hong Kong
Prior art keywords
benzimidazo
hydroxytryptamine
arylsulfonyl
piperazin
ligands
Prior art date
Application number
HK11113150.6A
Other languages
English (en)
Chinese (zh)
Inventor
．海達爾
．安德烈
．雲
．羅比喬德
Original Assignee
惠氏有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41404503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1158647(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 惠氏有限責任公司 filed Critical 惠氏有限責任公司
Publication of HK1158647A1 publication Critical patent/HK1158647A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/22—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK11113150.6A 2008-11-11 2011-12-06 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazo as 5-hydroxytryptamine-6 ligands 5--6 1-()-4-(-1-)-1h- HK1158647A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11329608P 2008-11-11 2008-11-11
PCT/US2009/063816 WO2010056644A1 (fr) 2008-11-11 2009-11-10 1-(arylsulfonyl)-4-(pipérazin-1-yl)-1h-benzimidazoles en tant que ligands de δ-hydroxytriptamine-6

Publications (1)

Publication Number Publication Date
HK1158647A1 true HK1158647A1 (en) 2012-07-20

Family

ID=41404503

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11113150.6A HK1158647A1 (en) 2008-11-11 2011-12-06 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazo as 5-hydroxytryptamine-6 ligands 5--6 1-()-4-(-1-)-1h-

Country Status (42)

Country Link
US (1) US8063053B2 (fr)
EP (1) EP2285784B1 (fr)
JP (1) JP5087171B2 (fr)
KR (1) KR101323417B1 (fr)
CN (1) CN102209713B (fr)
AP (1) AP2814A (fr)
AR (1) AR074325A1 (fr)
AU (1) AU2009314221B2 (fr)
BR (1) BRPI0920682A2 (fr)
CA (1) CA2740262C (fr)
CL (1) CL2011001050A1 (fr)
CO (1) CO6440548A2 (fr)
CR (1) CR20110247A (fr)
CU (1) CU24020B1 (fr)
CY (1) CY1113025T1 (fr)
DK (1) DK2285784T3 (fr)
DO (1) DOP2011000130A (fr)
EA (1) EA018369B1 (fr)
EC (1) ECSP11011045A (fr)
ES (1) ES2389694T3 (fr)
GE (1) GEP20135805B (fr)
HK (1) HK1158647A1 (fr)
HR (1) HRP20120561T1 (fr)
IL (1) IL212213A0 (fr)
MA (1) MA32788B1 (fr)
ME (1) ME01129B (fr)
MX (1) MX2011004996A (fr)
MY (1) MY156324A (fr)
NI (1) NI201100093A (fr)
NZ (1) NZ592563A (fr)
PE (1) PE20120026A1 (fr)
PL (1) PL2285784T3 (fr)
PT (1) PT2285784E (fr)
RS (1) RS52381B (fr)
SA (1) SA109300673B1 (fr)
SI (1) SI2285784T1 (fr)
SV (1) SV2011003902A (fr)
TN (1) TN2011000203A1 (fr)
TW (1) TWI481605B (fr)
UA (1) UA100192C2 (fr)
WO (1) WO2010056644A1 (fr)
ZA (1) ZA201103283B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101083986A (zh) * 2004-09-20 2007-12-05 泽农医药公司 双环杂环衍生物及其作为硬脂酰CoA去饱和酶(SCD)抑制剂的用途
BRPI0515478A (pt) * 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seu uso como mediadores de estearoil-coa-desaturase
AU2005329423A1 (en) * 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CN101084207A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
CN104557726B (zh) * 2013-10-19 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
WO2016004882A1 (fr) 2014-07-08 2016-01-14 Sunshine Lake Pharma Co., Ltd. Dérivés hétérocycliques aromatiques et leurs applications pharmaceutiques
WO2017052394A1 (fr) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Composés d'imidazopyridine et leur utilisation comme ligands du récepteur 5-ht6
EP3530651A1 (fr) * 2018-02-21 2019-08-28 Adamed sp. z o.o. Dérivés de l'indole et du benzimidazole comme antagonistes doubles des récepteurs 5-ht2a et 5-ht6

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9700693A (es) 1994-07-26 1997-04-30 Pfizer Derivados del 4-indol.
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
NZ501258A (en) 1997-07-11 2001-07-27 Smithkline Beecham P Benzenesulfonamide compounds with 5HT6 receptor antagonist activity for treating anxiety and/or depression
GB9716656D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
EP0930302B1 (fr) 1998-01-16 2003-04-02 F.Hoffmann-La Roche Ag Dérivés de benzosulfone
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
CN100396675C (zh) 1998-08-10 2008-06-25 加利福尼亚州大学董事会 质子泵抑制剂的前药
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
MXPA03003397A (es) 2000-10-20 2004-06-30 Biovitrum Ab N1-(bencensulfonil)indoles sustituidos en las posiciones 2-, 3-, 4-, o 5 y su uso en terapia.
SE0003810D0 (sv) * 2000-10-20 2000-10-20 Pharmacia Ab Novel compounds their use and preparations
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
AU2005102A (en) * 2000-11-02 2002-05-15 Wyeth Corp 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
CA2450245A1 (fr) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Derives de 4-piperazinylindole a affinite avec les recepteurs 5-ht6
WO2003026665A1 (fr) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Derives de 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine en tant qu'inhibiteurs de la kinase, notamment, des inhibiteurs de la kinase src
AU2003284142A1 (en) 2002-10-15 2004-05-04 Synta Pharmaceuticals Corp Aromatic bicyclic heterocyles to modulate 1L-12 production
TWI380816B (zh) 2004-04-13 2013-01-01 Synta Pharmaceuticals Corp 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑
JP2008508314A (ja) 2004-07-28 2008-03-21 アイアールエム・リミテッド・ライアビリティ・カンパニー ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders

Also Published As

Publication number Publication date
EA201100696A1 (ru) 2011-10-31
KR20110075013A (ko) 2011-07-05
CL2011001050A1 (es) 2011-08-19
IL212213A0 (en) 2011-06-30
SI2285784T1 (sl) 2012-08-31
MA32788B1 (fr) 2011-11-01
DK2285784T3 (da) 2012-07-23
BRPI0920682A2 (pt) 2016-09-27
JP5087171B2 (ja) 2012-11-28
MY156324A (en) 2016-02-15
CR20110247A (es) 2011-06-24
US8063053B2 (en) 2011-11-22
PE20120026A1 (es) 2012-02-12
WO2010056644A1 (fr) 2010-05-20
UA100192C2 (en) 2012-11-26
PT2285784E (pt) 2012-09-19
CN102209713A (zh) 2011-10-05
AR074325A1 (es) 2011-01-05
DOP2011000130A (es) 2017-04-30
SA109300673B1 (ar) 2013-05-25
CN102209713B (zh) 2014-07-02
CU24020B1 (es) 2014-07-30
GEP20135805B (en) 2013-04-10
CA2740262A1 (fr) 2010-05-20
AU2009314221A1 (en) 2010-05-20
AU2009314221B2 (en) 2012-08-30
AP2011005664A0 (en) 2011-04-30
ES2389694T3 (es) 2012-10-30
TN2011000203A1 (fr) 2012-12-17
CO6440548A2 (es) 2012-05-15
US20100120779A1 (en) 2010-05-13
KR101323417B1 (ko) 2013-10-29
ME01129B (me) 2013-03-20
NZ592563A (en) 2012-10-26
TWI481605B (zh) 2015-04-21
MX2011004996A (es) 2011-05-25
JP2012508275A (ja) 2012-04-05
ECSP11011045A (es) 2011-06-30
HRP20120561T1 (hr) 2012-07-31
CY1113025T1 (el) 2016-04-13
ZA201103283B (en) 2012-01-25
EA018369B1 (ru) 2013-07-30
TW201022247A (en) 2010-06-16
WO2010056644A8 (fr) 2010-11-18
RS52381B (en) 2012-12-31
AP2814A (en) 2013-12-31
CA2740262C (fr) 2013-05-28
PL2285784T3 (pl) 2012-12-31
NI201100093A (es) 2011-10-31
EP2285784B1 (fr) 2012-07-04
CU20110101A7 (es) 2012-01-31
SV2011003902A (es) 2011-07-05
EP2285784A1 (fr) 2011-02-23

Similar Documents

Publication Publication Date Title
HK1158647A1 (en) 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazo as 5-hydroxytryptamine-6 ligands 5--6 1-()-4-(-1-)-1h-
HRP20130698T1 (en) Novel phenylpyrazinones as kinase inhibitors
EP2449379A4 (fr) Nanoparticules fluorescentes à base de silice
HRP20170959T1 (hr) Farmaceutska suspenzija
EP2347395A4 (fr) Alerte de proximité géodépendante
IL207225A0 (en) Indazole derivatives
IL210935A0 (en) Anti-malarial compounds
IL211290A0 (en) New 2-amidothiadiazole derivatives
ZA201103462B (en) Aryl piperazine and their use as alpha2c antagonists
EP2253323A4 (fr) Agent antiallergique
HK1142781A1 (en) Liftable suspended cupboard
EP2382339A4 (fr) Compositions d'électrodéposition avec ligand à base d'amine
HK1178529A1 (en) Piperazines as antimalarial agents
ZA201004467B (en) Triazolopyridazines as pari inhibitors,production thereof,and use as medicaments
ZA201105219B (en) (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
EP2351742A4 (fr) Dérivé d indazole
ZA201104164B (en) Sulfamoyl-phenyl-ureido benzamidine-derivatives as antimalarial agents
EP2345644A4 (fr) Composé d indazole
GB0818365D0 (en) Quinoline compounds
AU323507S (en) Nasal pillows
GB0813166D0 (en) Fluid jack
TH0901002194B (th) อนุพันธ์อินดาโซลที่ถูกแทนที่ด้วยเฟนนิล และเบนโซไดออกซินิล
GB0820674D0 (en) Benzamide compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181110